EUVIMEDEUVIMED entdecken
Crossref

Formulation, Optimization and In-Vitro Assessment of a Montelukast Sodium-Loaded Proniosomal Gel for Sustained Drug Delivery in Asthma Management

Lalchand Devhare, Anitha K N, Kazi Sarfaraz Masoodali, Anita .A, Shobha A. Ubgade, Krishnakant B Bhelkar, Tufail Dana

International Journal of Drug Delivery Technology · 25.12.2025 · 15 (04)

DOI: 10.25258/ijddt.15.4.34 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Drug Delivery Technology, online erschienen am 25.12.2025. Verfasst von Lalchand Devhare und 6 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Montelukast Sodium is widely used for the management of asthma,but its low bioavailability due to the first-pass effect limits its therapeutic efficacy. A novel proniosomal gel-based delivery system can enhance EE, improve stability, and provide sustained drug discharge over an extended period.This study aims to formulate and assess a Montelukast Sodium proniosomal gel using different non-ionic surfactants, penetration enhancers, and gelling agents to optimize drug encapsulation, stability, and controlled drug discharge.Montelukast Sodium proniosomal gel was made using the coacervation phase separation approach. Varioussurfactants (Span 20/60/80, Tween 20/80), cholesterol (to control drug leakage), soya lecithin (as a penetration enhancer), and carbopol (as a gelling agent) were incorporated. The formulations were assessed for Fourier-transform infrared compatibility studies, vesicle size analysis, scanning electron microscopy (SEM), drug entrapment efficiency (EE), drug content, rheological behavior, in vitro drug discharge, and stability as per ICH Q1C guidelines.The study confirmed that Montelukast Sodium was successfully entrapped in all nine formulations. The type of surfactant and cholesterol content significantly influenced drug discharge and EE. FTIR analysis indicated no drug-excipient interactions, and SEM studies revealed uniform, spherical vesicles. The vesicle size of the optimized formulation (F2) ranged from 3.33±0.12 to 5.83±0.21 µm, with an EE of 54.46±0.50% and a drug discharge of 90.81±0.031%. The discharge kinetics followed a zero-order model and fitted the Higuchi equation, suggesting Super-Case II transport diffusion. Stability studies demonstrated that the formulation remained stable for 90 days, with the highest drug retention observed at 4°C.The optimized proniosomal gel formulation (F2) exhibited enhanced drug entrapment, prolonged drug discharge, and improved stability, making it a promising alternative for sustained delivery of Montelukast Sodium in asthma management.

Zitieren

APA

Devhare, L., N, A. K., Masoodali, K. S., .A, A., Ubgade, S. A., Bhelkar, K. B., & Dana, T. (2025). Formulation, Optimization and In-Vitro Assessment of a Montelukast Sodium-Loaded Proniosomal Gel for Sustained Drug Delivery in Asthma Management. International Journal of Drug Delivery Technology, 15(04). https://doi.org/10.25258/ijddt.15.4.34

Vancouver

Devhare L, N AK, Masoodali KS, .A A, Ubgade SA, Bhelkar KB, et al. Formulation, Optimization and In-Vitro Assessment of a Montelukast Sodium-Loaded Proniosomal Gel for Sustained Drug Delivery in Asthma Management. International Journal of Drug Delivery Technology. 2025;15(04). doi:10.25258/ijddt.15.4.34

BibTeX
@article{Devhare2025,
  author = {Devhare, Lalchand and N, Anitha K and Masoodali, Kazi Sarfaraz and .A, Anita and Ubgade, Shobha A. and Bhelkar, Krishnakant B and Dana, Tufail},
  title = {Formulation, Optimization and In-Vitro Assessment of a Montelukast Sodium-Loaded Proniosomal Gel for Sustained Drug Delivery in Asthma Management},
  journal = {International Journal of Drug Delivery Technology},
  year = {2025},
  volume = {15},
  number = {04},
  doi = {10.25258/ijddt.15.4.34}
}
Kostenlos starten →